TNFRSF17 and Miyoshi myopathy: Relapses often resulted from heterogenous BCMA expression within tumors, which led to outgrowth of antigen-low or negative MM cells [5, 6], suggesting that targeting of a single antigen may be insufficient to induce durable complete responses in a majority of patients.